Compare Marsh & McLennan Companies, Inc. (MRSH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs ResMed Inc. — how do they compare? Marsh & McLennan Companies, Inc. trades at $188.72 (market cap $91.27B), while ResMed Inc. trades at $225.83 (market cap $32.61B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 2.8× ResMed Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| MRSH | RMD | |
|---|---|---|
Market Cap | $91.27B | $32.61B |
Sector | Financials | Health |
52-Week High | $211.21 | $293.73 |
52-Week Low | $157.32 | $182.82 |
Enterprise Value | $111.95B | $31.97B |
Dividend Yield | 2.07% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $189.13, down 0.87% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats in Q2 2026, with EPS of $2.96 versus $2.88 expected, and 6% revenue growth highlight operational strength. The company announced the acquisition of Accel to expand its Midwest insurance reach, signaling strategic growth. Valuation metrics show a P/E of 23.35 and robust profitability with a net income margin of 14.24%.
The outlook remains positive with a consensus price target of $202.89, offering potential upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Bank of Nova Scotia increased holdings. The stock presents a solid long-term growth opportunity amid cyclical insurance sector headwinds.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
